Overview

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2030-12-30
Target enrollment:
Participant gender:
Summary
This clinical trial aims to evaluate the efficacy and safety of CAR-T cell therapy in patients with relapsed/refractory hematologic malignancies.
Phase:
NA
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Cell- and Tissue-Based Therapy